Join our daily newsletter At The Bell to receive exclusive market insights
- Chimeric Therapeutics (CHM) has given its first patient the second dose of Chlorotoxin CAR T cell therapy, targeting an aggressive cancer glioblastoma
- The company is currently conducting its phase one clinical trial at City of Hope, a world-renowned cancer treatment and research centre near Los Angeles
- The treatment of the first patient in the second dose marks the introduction of dual routes of administration
- On the market this morning, Chimeric is up 1.67 per cent and trading at 30.5 cents per share
Chimeric Therapeutics (CHM) has given its first patient the second dose of Chlorotoxin CAR T cell therapy.
Chlorotoxin targets recurrent or progressive glioblastoma (GBM), an aggressive type of cancer that begins within the brain.
The company is currently conducting its phase one clinical trial at City of Hope, a world-renowned cancer treatment and research centre near Los Angeles. The trial is testing the safety and tolerability of the drug.
The treatment of the first patient in the second dose marks the introduction of dual routes of administration of Chlorotoxin
City of Hope’s phase one clinical trial is expected to enroll between 18 and 36 patients with GBM.
“We are very encouraged by the continued progress of the trial, moving to this important next phase with dose escalation and dual routes of administration,” Chief Operating Officer Jennifer Chow said.
“This is another significant milestone in the development of this important therapy for patients with progressive or recurrent glioblastoma,” she added.
Notably, Chlorotoxin is also being investigated for development in patients with other solid tumors such as melanoma, small cell lung cancer, prostate cancer and colorectal cancer.
On the market this morning, Chimeric is up 1.67 per cent and trading at 30.5 cents per share at 12:23 am AEST.
